A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy
DESTINY-Breast05
Clinical Trial Program
A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy
Phase III
Status
Recruiting
Tumour subtype:
HER2+
Scenario
Adyuvante
SPONSOR
PRINCIPAL INVESTIGATORS
Sites
CENTRO ONCOLOGICO MD ANDERSON INTERNACIONAL ESPAÑA, CLÍNICA UNIVERSITARIA DE NAVARRA – MADRID, COMPLEJO HOSPITALARIO DE JAEN, COMPLEJO HOSPITALARIO DE NAVARRA, COMPLEJO HOSPITALARIO HOSPITAL “SAN PEDRO DE ALCANTARA”, COMPLEXO HOSPITALARIO UNIVERSITARIO A CORUÑA (HOSPITAL TERESA HERRERA), CONSORCIO HOSPITALARIO PROVINCIAL DE CASTELLON, HM PUERTA DEL SUR, HOSPITAL ARNAU DE VILANOVA DE VALENCIA, HOSPITAL CLINIC DE BARCELONA, HOSPITAL CLÍNICO UNIV. LOZANO BLESA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL DE FUENLABRADA, HOSPITAL DE LEÓN, HOSPITAL DE MATARÓ, HOSPITAL DE TORREVIEJA, HOSPITAL FUNDACIÓN JIMÉNEZ DÍAZ, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, HOSPITAL GENERAL UNIVERSITARIO J.M. MORALES MESEGUER, HOSPITAL MUTUA DE TERRASSA, HOSPITAL QUIRONSALUD SAGRADO CORAZON, HOSPITAL RAMON Y CAJAL, HOSPITAL SAN JUAN DE ALICANTE, HOSPITAL SON ESPASES, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI GENERAL DE CATALUNYA, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO BASURTO, HOSPITAL UNIVERSITARIO DE CANARIAS, HOSPITAL UNIVERSITARIO DE LA PAZ, HOSPITAL UNIVERSITARIO FUNDACIÓN DE ALCORCÓN, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO SAN CECILIO, HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA, HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA, HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, HU PUERTA DE HIERRO DE MAJADAHONDA, HU REY JUAN CARLOS, ICO BADALONA, ICO GIRONA (HOSPITAL DR. JOSEP TRUETA), ICO HOSPITALET (DURAN I REYNALS), INSTITUTO VALENCIANO DE ONCOLOGÍA, XANIT VITHAS INTERNACIONAL, HOSPITAL DEL MAR, CENTRO CLÍNICO FUNDAÇAO CHAMPALIMAUD, CENTRO HOSPITALAR LISBOA OCIDENTAL (HOSPITAL SAO FRANCISCO XAVIER), HOSPITAL BEATRIZ ANGELO, HOSPITAL CUF DESCOBERTAS, HOSPITAL DA LUZ, HOSPITAL DA SENHORA DA OLIVEIRA-GUIMARAES, IPO LISBOA (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL, EPE), IPO PORTO (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE PORTO FRANCISCO GENTIL, EPE )
